NEW YORK – Arbor Biotechnologies and Lonza said on Wednesday that they have forged a licensing agreement that will provide Lonza with access to Arbor's CRISPR-based gene editing technology.
Under the terms of the deal, Basel, Switzerland-based Lonza will be able to use Arbor's technology in its bioproduction products and services. Financial terms of the deal were not disclosed.
"Arbor's differentiated gene editing technologies allow Lonza to manufacture the next generation of therapeutics," Arbor CEO David Cheng said in a statement. "Arbor is committed to seeking and working with partners in this field to build an ecosystem for the research, development, and manufacturing of biological and cellular therapies."
Arbor, based in Cambridge, Massachusetts, was cofounded by Broad Institute scientists Winston Yan, David Scott, and Feng Zhang; and David Walt of Harvard University and the Wyss Institute.
The company emerged from stealth mode in 2018 with $15.6 million in Series A funding and a proprietary CRISPR enzyme called Cas13d.